The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the ...

researchers looked at the effect of the combined GLP-1 and GIP receptor agonist tirzepatide on cardiac structure and function in patients with heart failure with preserved ejection fraction (HFpEF) ...

Coronary artery calcium (CAC) scores have become a non-invasive way for physicians to easily determine how much plaque has built up inside a patient's coronary arteries, but the question has been how ...

Dow Jones media giant Disney, along with Meta stock, offer new buy points. Heico and FanDuel parent Flutter are near buy points.

A treatment need not meet certain criteria for efficacy to qualify an employee for FMLA leave, an agency official wrote in an ...

Trump Suggests Use of Emergency Powers and the Military for Deportations Donald Trump addressed his plans for mass deportations in a social media post. He is expected to interview candidates for ...